Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE4
4447 participants
INTERVENTIONAL
2021-09-30
2026-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Antibiotic Combination for H. Pylori Eradication in Penicillin-allergic Patients
NCT05023577
Susceptibility-Guided Therapy for Helicobacter Pylori Infection Treatment
NCT05250050
Bismuth-Metronidazole Triple Therapy for H. Pylori First-line Treatment
NCT04667299
PPI-amoxicillin for H. Pylori Treatment
NCT05014685
Eradication Efficacy and Safety of Two Rescue Treatments for Helicobacter Pylori Infection
NCT05176821
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
RBCL
Rabeprazole 20 mg bid, bismuth potassium citrate 0.6 g bid, clarithromycin 0.5 g bid and levofloxacin 0.5 g qd for 14 days
Rabeprazole
20mg bid
Bismuth potassium citrate
0.6g bid
Clarithromycin
0.5g bid
Levofloxacin
0.5g qd
RBLM
Rabeprazole 20 mg bid, bismuth potassium citrate 0.6 g bid, metronidazole 0.4 g qid and levofloxacin 0.5 g bid for 14 days
Rabeprazole
20mg bid
Bismuth potassium citrate
0.6g bid
Metronidazole
0.4g qid
Levofloxacin
0.5g qd
RBCM
Rabeprazole 20 mg bid, bismuth potassium citrate 0.6 g bid, metronidazole 0.4 g qid and clarithromycin 0.5 g bid for 14 days
Rabeprazole
20mg bid
Bismuth potassium citrate
0.6g bid
Metronidazole
0.4g qid
Clarithromycin
0.5g bid
RA
Rabeprazole 20 mg bid, and Amoxicillin 1.0 g tid for 14 days
Rabeprazole
20mg bid
Amoxicillin
1g tid
RAB
Rabeprazole 20 mg bid, bismuth potassium citrate 0.6 g bid, and Amoxicillin 1.0 g tid for 14 days
Rabeprazole
20mg bid
Bismuth potassium citrate
0.6g bid
Amoxicillin
1g tid
RAM
Rabeprazole 20 mg bid, metronidazole 0.4 g tid, and Amoxicillin 1.0 g tid for 14 days
Rabeprazole
20mg bid
Metronidazole
0.4g qid
Amoxicillin
1g tid
RBAM
Rabeprazole 20 mg bid, bismuth potassium citrate 0.6 g bid, metronidazole 0.4 g tid, and Amoxicillin 1.0 g tid for 14 days
Rabeprazole
20mg bid
Bismuth potassium citrate
0.6g bid
Metronidazole
0.4g qid
Amoxicillin
1g tid
RBAM4
Rabeprazole 20 mg bid, bismuth potassium citrate 0.6 g bid, metronidazole 0.4 g qid, and Amoxicillin 1.0 g tid for 14 days
Rabeprazole
20mg bid
Bismuth potassium citrate
0.6g bid
Amoxicillin
1g tid
Metronidazole
0.4g tid
RBDM
Rabeprazole 20 mg bid, bismuth potassium citrate 0.6 g bid, metronidazole 0.4 g qid and doxycycline 0.1 g bid for 14 days
Rabeprazole
20mg bid
Bismuth potassium citrate
0.6g bid
Metronidazole
0.4g tid
Doxycycline
0.1g bid
RBTM
Rabeprazole 20 mg bid, bismuth potassium citrate 0.6 g bid, metronidazole 0.4 g qid, and tetracycline 0.5 g qid for 14 days
Rabeprazole
20mg bid
Bismuth potassium citrate
0.6g bid
Metronidazole
0.4g tid
Tetracycline
0.5g qid
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Rabeprazole
20mg bid
Bismuth potassium citrate
0.6g bid
Metronidazole
0.4g qid
Clarithromycin
0.5g bid
Levofloxacin
0.5g qd
Amoxicillin
1g tid
Metronidazole
0.4g tid
Doxycycline
0.1g bid
Tetracycline
0.5g qid
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 18-75 years old on the day of signing the ICF.
* Helicobacter pylori infection confirmed by 13C-urea breath test or rapid urease test.
Exclusion Criteria
* Subjects or guardians refused to participate in the trial.
* Alcohol and/or drugs Abuse (addiction or dependence) or poor compliance with doctor's judgment.
* Have taken antibiotics, bismuth, proton pump inhibitors or Chinese traditional medicine 4 weeks before treatment.
* Pregnant or lactating women.
* Active peptic ulcer.
* allergic to drugs used in the trial.
* any other circumstances that are not suitable for recruitment.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shanghai Zhongshan Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Taotao Liu, MD
Role: PRINCIPAL_INVESTIGATOR
Fudan University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
B2021-376
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.